Skip to content
Review Open access

ctDNA in the Management of Resectable & Advanced Colorectal Cancer: Current Status and Future Directions

Sep 2026 · OncoTargets and Therapy · Vol 19 · 0 citations · 108 references
Medicine

TL;DR

Current professional guidance supports a cautious distinction between clinical validity and clinical utility: ctDNA can inform prognosis, counseling, and clinical-trial eligibility, but should not routinely replace standard surveillance or independently determine treatment escalation or de-escalation outside evidence-based indications or clinical trials.

Abstract

Abstract Circulating tumor DNA (ctDNA) is an increasingly important biomarker for molecular residual disease (MRD) after curative-intent treatment of colorectal cancer (CRC), but its prognostic value must be distinguished from proven clinical utility. This structured narrative review synthesizes evidence from PubMed/MEDLINE, Embase, ClinicalTrials.gov, and major oncology conference proceedings, covering stage I–III CRC and selected patients with resected or ablated oligometastatic stage IV disease. We review tumor-informed and tumor-agnostic assay strategies, postoperative sampling, serial versus landmark testing, low-shedding disease, clonal hematopoiesis, and major prospective and randomized studies. Postoperative ctDNA positivity consistently identifies patients at substantially increased risk of recurrence, while serial ctDNA dynamics provide additional prognostic information. In stage II colon cancer, the randomized DYNAMIC trial showed that a ctDNA-guided strategy reduced adjuvant chemotherapy use without compromising long-term recurrence outcomes. By contrast, DYNAMIC-III did not establish non-inferiority for ctDNA-guided de-escalation and showed no recurrence-free survival benefit from conventional chemotherapy escalation in ctDNA-positive stage III disease. The Phase III ALTAIR trial likewise did not meet its pre specified primary disease-free survival endpoint for treatment of molecular relapse with trifluridine/tipiracil. Current professional guidance therefore supports a cautious distinction between clinical validity and clinical utility: ctDNA can inform prognosis, counseling, and clinical-trial eligibility, but should not routinely replace standard surveillance or independently determine treatment escalation or de-escalation outside evidence-based indications or clinical trials. Future progress requires harmonized assays, randomized demonstration of outcome benefit, and prospective validation of integrated ctDNA, pathology, transcriptomic, and AI-derived risk models.

Read PDF

Similar papers

Review Open access Sep 2026

ctDNA-based detection of residual disease: implications for management of non-metastatic NSCLC

Despite advancements in perioperative and consolidative immunotherapy in early-stage to locally advanced non-small cell lung cancer (NSCLC), recurrence rates remain substantial. In this context, liquid biopsy has transformed the oncological landscape by enabling the non-invasive detection of tumor-derived components, i...

Charline Leclercq, M. Wespiser, G. Tachon et al. · 0 citations
Review Open access Sep 2026

Postoperative circulating tumor DNA in stage II colon cancer: biological rationale, clinical evidence, and unresolved challenges

Background Stage II colon cancer is clinically heterogeneous. Current clinicopathologic risk factors cannot accurately identify patients with residual disease after curative resection. Circulating tumor DNA (ctDNA) has emerged as a promising biomarker for the detection of minimal residual disease (MRD), defined as micr...

Er-Hua Yang, Xue-Feng Wang, Jia-Jing Zhang et al. · 0 citations
Open access Aug 2026

The role of circulating tumor DNA (ctDNA) to detect minimal residual disease in locally advanced gastroesophageal carcinoma: the BUTTERFLY study

Background Despite advances in perioperative and neoadjuvant strategies, patients with locally advanced gastroesophageal cancers remain at high risk of recurrence after curative intent treatment. No validated biomarkers are available to detect minimal residual disease (MRD) or to guide post-operative risk-adapted manag...

A. Puccini, L. Paracchini, R. Alfieri et al. · 0 citations
Open access 2026

Monitoring Molecular Residual Disease in Colorectal Cancer Using Tumor-Informed ctDNA Analysis

The findings suggest that tumor-informed ctDNA analysis provides a promising approach for post-operative MRD surveillance and recurrence risk stratification in CRC, however, the small sample size, lack of external validation, and absence of neoadjuvant-treated patients preclude definitive conclusions.

William C. Cho, Yingyu Wang, Qian-Qian Yao et al. · 0 citations
Aug 2026

P1.104. Potential Survival Benefit of Longitudinal ctDNA-Guided Treatment Adaptation in Advanced Esophageal Cancer

Esophageal Cancer: Management of Metastatic Cancer We have developed a tumor-specific circulating tumor DNA (ctDNA) monitoring test using digital PCR, termed the OTS (off-the-shelf)-assay. While recent attention has focused on minimal residual disease detection for early relapse diagnosis and to guide adju...

Takeshi Iwaya, Fumitaka Endo, R. Fujisawa et al. · 0 citations
Review Open access Aug 2026

Circulating tumor DNA-based minimal residual disease-guided adjuvant therapy in solid tumors: Current evidence, clinical trial frameworks, and future directions.

The postoperative management of resectable solid tumors depends on clinicopathological risk stratification. However, these static criteria often fail to identify occult minimal residual disease (MRD), resulting in suboptimal adjuvant treatment characterized by either overtreatment or undertreatment. Circulating tumor D...

Ming-Chi Ma, B. Xia, Qian Xu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.